

# Anna J Zaczek

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7890649/publications.pdf>

Version: 2024-02-01

55  
papers

1,098  
citations

430754

18  
h-index

434063

31  
g-index

56  
all docs

56  
docs citations

56  
times ranked

1930  
citing authors

#	ARTICLE	IF	CITATIONS
1	Breast cancer circulating tumor cells with mesenchymal featuresâ€”an unreachable target?. Cellular and Molecular Life Sciences, 2022, 79, 81.	2.4	12
2	Higher platelet counts correlate to tumour progression and can be induced by intratumoural stroma in non-metastatic breast carcinomas. British Journal of Cancer, 2022, 126, 464-471.	2.9	5
3	Chimeric virus-like particles presenting tumour-associated MUC1 epitope result in high titers of specific IgG antibodies in the presence of squalene oil-in-water adjuvant: towards safe cancer immunotherapy. Journal of Nanobiotechnology, 2022, 20, 160.	4.2	9
4	ER $\pm$ 36-High Cancer-Associated Fibroblasts as an Unfavorable Factor in Triple-Negative Breast Cancer. Cancers, 2022, 14, 2005.	1.7	1
5	Alpha-smooth muscle actin-positive cancer-associated fibroblasts secreting osteopontin promote growth of luminal breast cancer. Cellular and Molecular Biology Letters, 2022, 27, .	2.7	24
6	Reduced expression of innate immunity-related genes in lymph node metastases of luminal breast cancer patients. Scientific Reports, 2021, 11, 5097.	1.6	11
7	Cytocompatibility of stabilized black phosphorus nanosheets tailored by directly conjugated polymeric micelles for human breast cancer therapy. Scientific Reports, 2021, 11, 9304.	1.6	14
8	imPlatelet classifier: imageâ€”converted RNA biomarker profiles enable bloodâ€”based cancer diagnostics. Molecular Oncology, 2021, 15, 2688-2701.	2.1	16
9	Low Tumor-to-Stroma Ratio Reflects Protective Role of Stroma against Prostate Cancer Progression. Journal of Personalized Medicine, 2021, 11, 1088.	1.1	3
10	Diagnostic Accuracy of Liquid Biopsy in Endometrial Cancer. Cancers, 2021, 13, 5731.	1.7	13
11	microRNA Expression Profile in Single Hormone Receptor-Positive Breast Cancers Is Mainly Dependent on HER2 Statusâ€”A Pilot Study. Diagnostics, 2020, 10, 617.	1.3	7
12	Circulating Tumor Cells in Early and Advanced Breast Cancer; Biology and Prognostic Value. International Journal of Molecular Sciences, 2020, 21, 1671.	1.8	34
13	Liquid biopsy for minimally invasive heart transplant monitoring: a pilot study. Journal of Clinical Pathology, 2020, 73, 507-510.	1.0	4
14	Low Numbers of Vascular Vessels Correlate to Progression in Hormone-Na $\tilde{v}$ e Prostate Carcinomas Undergoing Radical Prostatectomy. Cancers, 2019, 11, 1356.	1.7	7
15	Clinical and Biological Significance of ESR1 Gene Alteration and Estrogen Receptors Isoforms Expression in Breast Cancer Patients. International Journal of Molecular Sciences, 2019, 20, 1881.	1.8	8
16	Sensitive detection of caspase-3 enzymatic activities and inhibitor screening by mass spectrometry with dual maleimide labelling quantitation. Analyst, The, 2019, 144, 6751-6759.	1.7	6
17	The Prognostic Significance of Eukaryotic Translation Initiation Factors (eIFs) in Endometrial Cancer. International Journal of Molecular Sciences, 2019, 20, 6169.	1.8	9
18	NF-kappa B Signaling-Related Signatures Are Connected with the Mesenchymal Phenotype of Circulating Tumor Cells in Non-Metastatic Breast Cancer. Cancers, 2019, 11, 1961.	1.7	18

#	ARTICLE	IF	CITATIONS
19	Spectrum of Epithelial-Mesenchymal Transition Phenotypes in Circulating Tumour Cells from Early Breast Cancer Patients. <i>Cancers</i> , 2019, 11, 59.	1.7	47
20	Sensitive Detection of Single-Cell Secreted H <sub>2</sub> O <sub>2</sub> by Integrating a Microfluidic Droplet Sensor and Au Nanoclusters. <i>Analytical Chemistry</i> , 2018, 90, 4478-4484.	3.2	77
21	Aggressive Phenotype of Cells Disseminated via Hematogenous and Lymphatic Route in Breast Cancer Patients. <i>Translational Oncology</i> , 2018, 11, 722-731.	1.7	19
22	MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma. <i>Lung Cancer</i> , 2018, 118, 111-118.	0.9	38
23	RSK1 promotes murine breast cancer growth and metastasis. <i>Folia Histochemica Et Cytobiologica</i> , 2018, 56, 11-20.	0.6	5
24	The Landscape of Circulating Tumor Cell Research in the Context of Epithelial-Mesenchymal Transition. <i>Pathobiology</i> , 2017, 84, 264-283.	1.9	16
25	Fibroblast growth factor signalling induces loss of progesterone receptor in breast cancer cells. <i>Oncotarget</i> , 2016, 7, 86011-86025.	0.8	18
26	Keratin 7 expression in lymph node metastases but not in the primary tumour correlates with distant metastases and poor prognosis in colon carcinoma. <i>Polish Journal of Pathology</i> , 2016, 3, 228-234.	0.1	14
27	HOTAIR in Relation to Epithelial-Mesenchymal Transition and Cancer Stem Cells in Molecular Subtypes of Endometrial Cancer. <i>International Journal of Biological Markers</i> , 2016, 31, 245-251.	0.7	21
28	Interactions between FGFR2 and RSK2—implications for breast cancer prognosis. <i>Tumor Biology</i> , 2016, 37, 13721-13731.	0.8	11
29	Endometrial cancer in patients after previous neoplastic disease—clinical and molecular aspects.. <i>Ginekologia Polska</i> , 2016, 87, 88-93.	0.3	0
30	CD99 correlates with low cyclin D1, high topoisomerase 2 $\alpha$ status and triple negative molecular phenotype but is prognostically irrelevant in breast carcinoma. <i>Polish Journal of Pathology</i> , 2015, 3, 269-275.	0.1	4
31	Stromal expression of ALDH1 in human breast carcinomas indicates reduced tumor progression. <i>Oncotarget</i> , 2015, 6, 26789-26803.	0.8	18
32	Immunohistochemical characterisation of molecular subtypes in endometrial cancer. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 21981-90.	1.3	3
33	A multimarker qPCR platform for the characterisation of endometrial cancer. <i>Oncology Reports</i> , 2014, 31, 1003-1013.	1.2	6
34	HER2-Positive Endometrial Cancer Subtype Carries Poor Prognosis. <i>Clinical and Translational Science</i> , 2014, 7, 482-488.	1.5	26
35	Are bilateral breast cancers and breast cancers coexisting with ovarian cancer different from solitary tumors? A pair-matched immunohistochemical analysis aimed at intrinsic tumor phenotype. <i>Pathology International</i> , 2014, 64, 508-517.	0.6	3
36	Phosphorylation of RSK2 at Tyr529 by FGFR2-p38 enhances human mammary epithelial cells migration. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2014, 1843, 2461-2470.	1.9	20

#	ARTICLE	IF	CITATIONS
37	Tumor Heterogeneity at Protein Level as an Independent Prognostic Factor in Endometrial Cancer. <i>Translational Oncology</i> , 2014, 7, 613-619.	1.7	28
38	Mesenchymal Phenotype of CTC-Enriched Blood Fraction and Lymph Node Metastasis Formation Potential. <i>PLoS ONE</i> , 2014, 9, e93901.	1.1	43
39	Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis aimed at intrinsic tumor phenotype. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 353-63.	0.5	9
40	Epithelial-mesenchymal transition markers in lymph node metastases and primary breast tumors - relation to dissemination and proliferation. <i>American Journal of Translational Research (discontinued)</i> , 2014, 6, 793-808.	0.0	20
41	Are bilateral breast cancers different from breast cancers coexisting with ovarian cancer? An immunohistochemical analysis aimed at intrinsic tumor phenotype. <i>Breast</i> , 2013, 22, 425-430.	0.9	1
42	Heterogeneity of Mesenchymal Markers Expression – Molecular Profiles of Cancer Cells Disseminated by Lymphatic and Hematogenous Routes in Breast Cancer. <i>Cancers</i> , 2013, 5, 1485-1503.	1.7	8
43	Prognostic Significance of ESR1 Amplification and ESR1 PvuII, CYP2C19*2, UGT2B15*2 Polymorphisms in Breast Cancer Patients. <i>PLoS ONE</i> , 2013, 8, e72219.	1.1	20
44	Epithelial-mesenchymal transition and cancer stem cells in endometrial cancer. <i>Anticancer Research</i> , 2013, 33, 5461-9.	0.5	14
45	Prognostic Significance of <i>TOP2A</i> Gene Dosage in HER-2-Negative Breast Cancer. <i>Oncologist</i> , 2012, 17, 1246-1255.	1.9	22
46	CD73 Expression as a Potential Marker of Good Prognosis in Breast Carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2012, 20, 103-107.	0.6	68
47	Deregulation of RAD21 and RUNX1 expression in endometrial cancer. <i>Oncology Letters</i> , 2012, 4, 727-732.	0.8	26
48	Epithelial-Mesenchymal Transition: A Hallmark in Metastasis Formation Linking Circulating Tumor Cells and Cancer Stem Cells. <i>Pathobiology</i> , 2012, 79, 195-208.	1.9	168
49	Expression of epithelial to mesenchymal transition-related markers in lymph node metastases as a surrogate for primary tumor metastatic potential in breast cancer. <i>Journal of Translational Medicine</i> , 2012, 10, 226.	1.8	41
50	Prognostic Value of TOP2A Gene Amplification and Chromosome 17 Polysomy in Early Breast Cancer. <i>Pathology and Oncology Research</i> , 2012, 18, 885-894.	0.9	21
51	Clinical evaluation of developed PCR-based method with hydrolysis probes for TOP2A copy number evaluation in breast cancer samples. <i>Clinical Biochemistry</i> , 2010, 43, 891-898.	0.8	10
52	Pharmacogenetics in breast cancer hormone therapy. <i>Wspolczesna Onkologia</i> , 2010, 4, 242-247.	0.7	0
53	Gene copy numbers of HER family in breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007, 134, 271-279.	1.2	22
54	(CA) <sub>n</sub> Microsatellite polymorphism of ERBB-1 in breast cancer. <i>European Journal of Cancer</i> , 2006, 42, 1698-1701.	1.3	2

#	ARTICLE	IF	CITATIONS
55	p53 Gene status in relation to ex vivo chemosensitivity of non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2002, 128, 141-147.	1.2	28